Where does CG Oncology, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), CG Oncology, Inc. ranks #45,581 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does CG Oncology, Inc. hold?

CG Oncology, Inc. holds 5 US utility patents granted between 2022 and 2025, spanning 5 technology areas.

What is CG Oncology, Inc.'s Innovation Score?

CG Oncology, Inc. has an Innovation Score of 47.9 out of 100 (top 18% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does CG Oncology, Inc. focus on?

CG Oncology, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 5 patents, ranking #3,434 of 6,058 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Is CG Oncology, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for CG Oncology, Inc..

What does claim depth mean for CG Oncology, Inc.'s patents?

CG Oncology, Inc.'s patents average 23.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the CG Oncology, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

CG Oncology, Inc.

USPTO PatentsView assignee record - 5 granted patents across 5 technology areas, recorded in grant years 2022–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, CG ranks #45,581 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 5 technology areas.

#45,581
of 49,997 US assignees by volume: Top 18%
by Innovation Score (47.9/100): 23.0
avg claims per patent

USPTO PatentsView assignee plate

Corpus R45581 · US Corporation #45,581 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 5 grants
BOTTOM-DECILE #45,581/49,997
PHOTO-FINISH Cesium AB
CPC-NARROW A61P · 5 areas
INNOV-PAR 47.9/100
CLAIMS-DENSE 23.0 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2022–2025 · 4y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Cesium AB (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How CG’s 47.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.2 pts (13%) Velocity 20.0 pts (42%) Breadth 7.9 pts (16%) Claim depth 13.8 pts (29%)

Qualcomm Incorporated · highest

85
Belvac Production… · near

48
Brose Fahrzeugteile… · near

48
CG Oncology · this assignee

48
Mapi Pharma · near

48
UPM Raflatac OY · near

48
3D Lighting… · lowest

7

What this shows CG's Innovation Score is 47.9/100 (top 18% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for CG?

Each dot is one of CG’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). CG’s own 23.0 claims/patent is ABOVE the 12.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

CG vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where CG's grants concentrate

CG Oncology, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2022 (2 grants) versus a trough of 1 in 2023. By volume, CG sits between Cesium AB and Chain Reaction Ltd..

CG's three-year grant acceleration

CG Oncology, Inc. shows 4 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Cesium AB

5
Ceva Animal Health

5
CFS Brands

5
CFT S P A

5
Cgtech

5
Cgenetech (Suzhou…

5
Chacha Search

5
Chain Reaction

5
CG Oncology ◀

5

What this shows CG holds 5 patents at rank #45,493, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near CG

By rank, the assignees closest to #45,493 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in CG's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for CG, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), CG ranks #3,434 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (48 here).

Mapi Pharma Ltd. 48 Belvac Production Machinery, Inc. 48 UPM Raflatac OY 48 Brose Fahrzeugteile GmbH & Co. KG, Hallstadt 48

CG's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

48 Top 18% higher than 82% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2022–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.

View data table

CG Oncology, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2022	2	40.0%
2023	1	20.0%
2024	1	20.0%
2025partial year	1	20.0%

Which technologies does CG Oncology, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 5

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 5

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 5

C07K - Peptides 2

Y02A - Technologies FOR Adaptation TO Climate Change 2

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

CG Oncology, Inc.'s patent record in context - here's where to go next.

CG Oncology, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #45,581 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare CG Oncology, Inc. against Cesium AB, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 47.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.